The impact of age on prostate cancer progression and quality of life in active surveillance patients

Abstract

Active surveillance (AS) represents a paradigm change in the management of low-risk prostate cancer. In appropriately selected patients, AS has been demonstrated to reduce the over-treatment of indolent prostate cancers with improvement in quality of life (QOL) with the caveat that the diagnosis of lethal malignancies remain feasible while the cancer remains curable. 1,2 Multiple AS studies have documented prostate cancer specific survival rates of 94-99.9% at 15 years with non-prostate cancer deaths being 9-24 times more likely. 3,4 AS protocols are hampered by a lack of consensus regarding standardized criteria for inclusion, follow-up, and the initiation of therapeutic intervention. 3-5 In particular, definitive local therapy is often recommended to healthy younger men with low-risk features due to a

Eye of the beholder—Tales from Prostate Cancer Active Surveillance Development

“…Of eight studies that passed eligibility, five supported hydrophilic‐coating, and the authors dive into the details of the conflicting results with an overall favourable rating of the cost‐effective and quality of life merits. To the Clinic… We have three articles in this section. Merrick et al 5 have the themed article mentioned above on active surveillance. This is an interesting cohort with all patients staged with a transperineal mapping biopsy—hoping to exclude under‐graded patients.…”

“… To the Clinic… We have three articles in this section. Merrick et al 5 have the themed article mentioned above on active surveillance. This is an interesting cohort with all patients staged with a transperineal mapping biopsy—hoping to exclude under‐graded patients.…”